Regeneron CEO says Amgen not putting patients first in patent dispute

(Reuters) - Regeneron Pharmaceuticals Chief Executive Len Schliefer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out.